SpyGlass Pharma

SpyGlass Pharma (Ticker: SGP US) develops drug-delivery systems designed to provide sustained treatment for chronic eye conditions. Its BIM-IOL System attaches drug pads to an artificial lens implanted during cataract surgery and is designed to deliver bimatoprost for three years. Two late-stage Phase 3 clinical trials of the system, intended to support registration, began in July 2025. SpyGlass Pharma is headquartered in Aliso Viejo, California, and its CEO is Patrick Mooney. Its investors include New Enterprise Associates and RA Capital.

The scheduled listing date on Nasdaq was February 6, 2026. The proposed offering comprises 9,375,000 shares at an indicative price range of $15.00–17.00 per share. At the indicative range midpoint, the base offering would represent $150.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $549.00 million.

Jefferies, Leerink Partners, Citigroup, and Stifel are offering managers.